The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

By the end of the trial, those who took Zepbound lost about 20% of their body weight on average, compared with a nearly 14% ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

A new study shows Zepbound beats Wegovy for weight loss. "It's NOT normal to snore; get it checked out. Sleep apnea worsens ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...